/2 Study of the Highly-selective RET , Pralsetinib (BLU-667), in Patients With Thyroid , Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

  • Cancer
  • Tumor
  • Neoplasms
  • Respiratory Tract Neoplasms
  • Lung Cancer
  • Lung Neoplasm
  • Neuroendocrine Carcinoma
  • Solid Tumors
  • Thyroid Cancer
  • Medullary Thyroid Cancer
  • Thoracic Neoplasms
  • Head and Neck Cancer
  • Head and Neck Neoplasms